Moladerm

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Moladerm

What is Moladerm? Identity and Composition

Property Description
Active ingredient Miconazole Nitrate
Form Cream, Spray, Powder, Gel
Pharmacological class Antifungal medication (Imidazole derivative)
Common use Fungus infections of the skin
Origin Synthetic Azole derivative

Moladerm is a pharmaceutical preparation classified as a broad-spectrum antifungal medication, designed specifically to address infections caused by various fungal and yeast organisms. The drug's core component is the active ingredient, Miconazole Nitrate, which is a single-ingredient product responsible for its anti-infective agent properties. This compound is a synthetic Azole derivative, placing it within the Imidazole antifungal subclass, a pharmacological group that is clinically recognized for its effectiveness against superficial mycoses. This category of medication helps manage the growth of the fungi causing the infection.

Drug Forms and Topical Application: Differentiation

The identity of Moladerm is specifically tied to its topical application and mucocutaneous application as opposed to systemic delivery. The active compound is formulated into several practical pharmaceutical forms to facilitate this, including a cream base, a spray, a powder, a solution, a vaginal suppository, and an oral gel. This wide variety of forms distinguishes the Miconazole Nitrate molecule, making it a versatile resource for conditions such as Athlete's foot, jock itch, or cutaneous candidiasis. The compound is an established treatment for localized fungal issues and is utilized in dermatological preparations intended for direct application to the skin.

Core Purpose of this Antifungal Medication

The primary purpose of the medication is to achieve fungistasis and execute antifungal activity against susceptible organisms, thereby helping to clear up fungus infections of the skin. The Miconazole component achieves this effect by interfering with the vital process of inhibiting fungal growth through the disruption of the fungal cell membrane integrity. By providing this targeted support, Moladerm offers fundamental relief in managing common superficial conditions such as dermatophytoses and mucocutaneous candidiasis, which are the main conditions its broad-spectrum action is designed to counteract.

What side effects are possible with Moladerm?

The safety profile for Moladerm, containing Miconazole Nitrate, is primarily characterized by localized reactions at the application site, as documented in official regulatory sources. The most frequently documented adverse effects are generally non-systemic.

Adverse Reaction Scope

Component Regulatory Focus
Frequency classification Uncommon (occurring in ge 1/1,000 to < 1/100) for local effects like skin burning sensation and application site irritation. Not Known for severe reactions like anaphylactic shock.
System-organ classes involved Skin and Subcutaneous Tissue Disorders, General Disorders and Administration Site Conditions, and Immune System Disorders.
Serious adverse reactions Anaphylactic reaction and severe hypersensitivity reactions (including angioedema) are documented under the Immune System Disorders classification.

Safety Considerations and Constraints

Official labeling includes several constraints regarding use and specific populations:

  • Pediatric Population: Use is generally contraindicated in children under 2 years of age unless specifically directed by a healthcare provider. Safety and efficacy have not been established in very young infants (less than 4 weeks of age).
  • Interaction Caution: Caution is required with the concurrent use of Vitamin K antagonists (e.g., Warfarin), as there is a documented potential for the enhancement of the anticoagulant effect, which necessitates monitoring.
  • Material Restriction: Formulation ingredients may damage latex products such as contraceptive diaphragms or condoms, and contact should be avoided.
  • Duration of Use: Some formulations carry a safety note that use for longer than 7 days is not known to be safe in specific contexts.
  • Contraindication: Hypersensitivity to the active substance or other imidazole derivatives is a formal contraindication.

The official safety information structures the understanding of Moladerm's risks by establishing that the most common issues are localized and non-systemic, while acknowledging the low but serious risk of systemic allergic events. The profile defines explicit age-based limitations and high-level interaction cautions (e.g., Warfarin, latex damage), ensuring the communicated risk is strictly aligned with official regulatory constraints and classifications.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Miconazole Nitrate (Moladerm) overdose describes manifestations primarily related to accidental exposure or excessive use. Systemic overdose is typically associated with accidental oral ingestion of the formulation.

Documented Overdose Manifestations

Exposure Type Documented Manifestations
Accidental Oral Ingestion Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and upper abdominal pain.
Excessive Topical Use Local skin irritation at the application site, such as burning or inflammation.

Required Emergency Actions

Immediate medical attention is mandatory for certain life-threatening situations. Following any confirmed or suspected accidental oral ingestion, emergency services or a Poison Control Center must be contacted immediately, as advised in regulatory labeling. Urgent medical care is also required if severe systemic symptoms develop, such as signs of anaphylaxis or other severe hypersensitivity reactions.

Crucially, in patients concurrently taking oral anticoagulants (e.g., Warfarin), an overdose carries a documented risk of severe bleeding events and an increased International Normalized Ratio (INR); these individuals require immediate hospital monitoring of their coagulation status. Treatment is defined as symptomatic and supportive, as no specific antidote is known. Regulatory documents also note that the excipient Benzoic acid may increase the risk of jaundice in newborns (up to 4 weeks old) upon excessive exposure.

Therapeutic Uses of Moladerm

What Moladerm Treats: Main Uses and Benefits

Moladerm is relevant for easing symptoms that interfere with daily comfort, focusing on topical fungal and yeast infections. This type of treatment is commonly used across conditions presenting with acute episodes of skin infection, contributing to easing the overall symptom load.

The application is generally appropriate for managing symptomatic discomfort associated with Tinea corporis (ringworm), Tinea pedis (athlete's foot), Tinea cruris (jock itch), cutaneous Candidiasis, and Tinea Versicolor. These scenarios often involve symptoms related to inflammatory or irritative states, such as redness, burning, and scaling.

The overall purpose of supportive management in this context is patient-focused:

“The product may assist with maintaining functional stability and supports general well-being during symptomatic phases.”

Moladerm is relevant when short-term symptomatic assistance is needed to address symptom clusters that may become intense or disruptive.

Quick Fact: Relief for Persistent Itching

Moladerm is commonly used to help with the pronounced itching and discomfort characteristic of these skin infections.

Eligibility and Restrictions for Use

Who Can and Cannot Use Moladerm?

Moladerm's eligibility is determined by official population-based rules from regulatory documents, primarily focusing on age, application site, and hypersensitivity status.

Eligibility Scope

Classification Population Rule Status
Contraindication Hypersensitivity to Miconazole, Imidazole antifungals, or excipients. Must not use
Age Restriction Children under 2 years of age. Not recommended (unless physician-directed)
Prohibited Use Ophthalmic (eye), oral, or intravaginal application (for topical skin forms). Prohibited
Conditional Use Patients concurrently taking Warfarin or oral anticoagulants. Caution Required
Physiological Status Pregnancy and Lactation. Use with caution

Age-Related Eligibility

Adults and Adolescents are eligible for use under standard labeled conditions. Use is permitted in children aged 2 years and older, though supervision is required. Safety and efficacy have not been established in infants less than four weeks of age.

Condition-Specific Eligibility

No explicit contraindication or restriction is documented regarding hepatic or renal impairment for the topical formulation, reflecting minimal systemic absorption. Use during pregnancy and breastfeeding requires caution, and a careful assessment is advised by regulatory agencies.

What should I know about interactions with other medicines?

Moladerm Interactions with other medicines and products

Official regulatory information describes a number of pharmacokinetic and pharmacodynamic interactions for Moladerm, primarily due to its role as a substrate for the metabolic enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp).

Documented Interaction Categories and Agents

Interaction Type Interacting Medicines/Categories
Increased Moladerm Exposure Strong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir), strong P-gp inhibitors, grapefruit juice.
Decreased Moladerm Exposure Strong CYP3A4 inducers (e.g., Rifampin, Carbamazepine), strong P-gp inducers, St. John's Wort.
Altered Co-administered Drug Exposure Substrates of OATP1B1/OATP1B3 transporters (e.g., Cyclosporine).

Restrictions and Requirements

Co-administration with strong CYP3A4 inhibitors or dual CYP3A4/P-gp inhibitors is contraindicated due to the resulting significant increase in Moladerm's systemic concentration, which may lead to serious consequences. For other interacting medicinal products that are moderate inhibitors or inducers of these pathways, dose adjustments to either Moladerm or the co-administered drug may be required to maintain exposure within the approved range. The official labeling specifies that certain strong inducers, such as St. John's Wort, must be avoided entirely.

Patients with underlying hepatic impairment may be more susceptible to elevated Moladerm concentrations when combined with enzyme or transporter inhibitors. Grapefruit juice and certain alcohol-containing beverages are listed as products that may alter drug absorption and systemic exposure and should be limited or avoided.

Mechanism of Action

How Moladerm Works

Moladerm (Miconazole Nitrate) functions through a specific, enzyme-mediated process that targets the structural integrity of fungal pathogens. Its action is strictly peripheral, aiming to dismantle the fungal cell from the molecular level upwards.


Enzyme Inhibition and Sterol Depletion

The drug's primary mechanism involves the non-competitive inhibition of lanosterol 14alpha-demethylase (14alpha-DM), a crucial cytochrome P450 enzyme present only in fungi. This blockade halts the necessary conversion of lanosterol into ergosterol, the vital sterol required for building the fungal cell membrane. This molecular step initiates a mechanistic cascade.


Cascade to Cell Membrane Lysis

The resulting ergosterol depletion compromises the fungal cell's structural integrity, reducing its fluidity and stability. Simultaneously, toxic molecular precursors, like 14alpha-methyl sterols, accumulate, further destabilizing the membrane and organelles. This cytotoxic cascade leads directly to the loss of osmotic control and the eventual physical lysis (destruction) of the fungal cell (a fungicidal effect at high local concentrations), resulting in the elimination of the pathogenic organism.

Dosage and Administration Information

Moladerm (Miconazole Nitrate) is used according to specific instructions for its various forms, which are administered via three established routes: topical (cutaneous), intravaginal, or oromucosal (oral cavity). Its use is strictly procedural, with a defined dose, frequency, and duration that varies by the product and the application site.

Administration Routes and Standard Regimens

Application Route Typical Frequency & Dose Standard Duration
Topical (Cutaneous) Apply a thin layer twice daily (morning and night) 2 to 4 weeks (4 weeks for Athlete's Foot; 2 weeks for Jock Itch)
Intravaginal Once daily at bedtime (100 mg or 200 mg suppository, or 2% cream) 3-day or 7-day regimens, depending on formulation
Oromucosal (Oral Gel) 2.5 mL applied four times a day Generally 7 to 14 days

Usage Instructions and Duration

For cutaneous application, the affected area must be cleaned and dried thoroughly before use, and the cream must be rubbed into the skin until fully penetrated. Treatment for skin infections should be continued for at least one week after the visual signs and symptoms have disappeared to prevent relapse. If a dose is missed, it should be applied as soon as possible, or skipped if the time for the next scheduled dose is near. Pediatric use for cutaneous infections is generally recommended for children 2 years of age and older, following the adult dosing schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Moladerm


Evidence for Tinea Infections (Athlete’s Foot, Ringworm, Jock Itch)

The research on Moladerm's active ingredient (Miconazole Nitrate) for common skin infections, like athlete's foot (Tinea pedis), ringworm (Tinea corporis), and jock itch (Tinea cruris), relies mainly on short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time and focused on populations of adults with microbiologically confirmed infections. Researchers examined outcomes such as changes in visible signs, which were outcomes linked to inflammatory or irritative states, and the non-detection of the fungus, confirmed by laboratory tests.

Studies monitored patterns related to changes in physical signs and the non-detection of the organism during the observation periods. Findings describe patterns observed in the studies, and research highlights changes measured during the study period, contributing to the broader evidence landscape for superficial fungal issues. Longer-term recurrence rates after the study observation period were not the primary focus of these pivotal studies. Comparative evidence regarding symptom changes against a wide range of other available treatments is not consistently detailed in regulatory summaries.


Evidence for Cutaneous and Vulvovaginal Candidiasis

Moladerm was studied for conditions characterized by fluctuating or episodic manifestations, specifically yeast infections of the skin (cutaneous candidiasis) and vaginal yeast infections (vulvovaginal candidiasis). Research for both uses was evaluated in numerous short-course RCTs. These trials explored short-term symptom changes, monitoring patient-reported outcomes describing perceived discomfort and lab-confirmed non-detection of the yeast organism. For vulvovaginal use, studies monitored different treatment durations and formulations, such as creams versus suppositories. Regimens of varying duration were studied for their association with changes in clinical and mycological measurements in many of the women included in the trials.

What remains uncertain is the durability of the response for the long term, as follow-up durations were limited immediately following treatment completion. For vulvovaginal use, research describes that findings were mixed regarding non-detection rates for certain non-Candida albicans species of yeast, suggesting certainty remains low for these specific organisms.


Evidence in Specific Patient Populations and Research Gaps

Moladerm was evaluated in adults across all indications, and in some studies, pediatric patients were included, particularly infants (e.g., ge 4 weeks old) with candidal diaper rash. However, data for certain groups remain insufficient. The evidence quality varies across studies, with extensive data supporting the short-term use for common fungal skin infections. Conversely, the evidence for nail fungus (Onychomycosis) is limited, primarily restricted to patients with mild-to-moderate forms of the condition. Findings were mixed in these smaller-scale studies, and sample sizes were modest. The research primarily focuses on short-term symptom patterns; consequently, there is limited information for long-term outcomes like chronic recurrence prevention.

Key Studies & References

  1. Efficacy of topical antifungal drugs in different dermatomycoses: a systematic review with meta-analysis (Miconazole, Tinea/Cutaneous Candidiasis)

Frequently Asked Questions (FAQ)

Common questions about Moladerm (FAQ)

Q: Is Moladerm used for more than one medical condition?

According to the official regulatory labeling, Moladerm is approved for the treatment of several medical conditions caused by fungi and yeast. These indications include common superficial mycoses such as Athlete’s Foot, Ringworm, and Jock Itch, as well as cutaneous (skin) and vulvovaginal (vaginal) candidiasis.

Q: What is the difference between Moladerm and an over-the-counter treatment?

Moladerm (Miconazole Nitrate) is the active ingredient found in several pharmaceutical products. Some specific formulations are classified by regulatory agencies as Over-the-Counter (OTC) drugs, available without a prescription. Other forms, depending on their strength or specific indication, may be classified as Prescription-only (Rx-only). The classification depends on the specific drug form, concentration, and regulatory approval.

Q: Why is Moladerm sometimes described as a 'selective' treatment?

Moladerm's mechanism of action, as described in official documents, is based on a targeted process within the organism. It inhibits the enzyme lanosterol 14alpha-demethylase, which is a crucial component of the fungal cell structure and is present only in fungi, making its action specific to the pathogenic organism.

Q: Can Moladerm be taken by people who have mild kidney problems?

Official labeling for the topical formulation generally does not document explicit contraindications regarding mild hepatic (liver) or renal (kidney) impairment. This is often because systemic absorption of the drug when applied to the skin is minimal. However, safety data specifically for patients with severe impairment is generally limited in the official information.

Q: Does Moladerm usually require blood tests or other monitoring?

Standard monitoring is primarily required when Moladerm is co-administered with certain high-risk medications. Regulatory warnings specifically caution that concurrent use with Vitamin K antagonists (e.g., Warfarin) necessitates the monitoring of laboratory blood parameters due to the potential for an enhanced anticoagulant effect.

Q: Why is it important to know about all my medications before starting Moladerm?

Knowing all current medications is essential because co-administration with strong inhibitors of the CYP3A4 or P-gp enzymes can significantly increase Moladerm’s concentration in the body. Official regulatory documents stress that this increase may lead to serious consequences, highlighting the need for a full medication review.

Q: Why are people often told about potential interactions when starting Moladerm?

Patients are informed about potential interactions because Moladerm can significantly alter the level of other co-administered medications, such as blood thinners or specific metabolic substrates. Official documents detail these pharmacokinetic risks, indicating that full awareness is necessary to mitigate serious consequences resulting from drug-drug interactions.

Q: Are there any common foods or drinks that might interfere with Moladerm?

Official drug information notes that certain products can interfere with systemic exposure to the medicine. Specifically, grapefruit juice and certain alcohol-containing beverages are listed as agents that may alter drug absorption, and official information suggests limiting or avoiding their concurrent use.

Q: Are there any known interactions between Moladerm and alcohol consumption?

Yes, official regulatory labeling lists certain alcohol-containing beverages as products that may alter the systemic exposure or absorption of the medication. For this reason, official documentation cautions that these beverages may alter drug absorption, and concurrent use may be limited or avoided as described in the official guidance.

Q: Are there any known interactions between Moladerm and herbal supplements?

Regulatory information on drug interactions identifies certain potent herbal products that are noted to have interactions. For instance, the strong enzyme inducer St. John's Wort is officially designated to be avoided entirely due to its potential to decrease the body’s exposure to the drug.

Q: Does Moladerm interact with common pain relievers like ibuprofen?

Official documents state that Moladerm can interact with other drugs that affect specific enzyme and transporter pathways in the body (such as CYP3A4). If a common pain reliever affects these pathways, an interaction is possible. A complete review of all medications is generally necessary before starting treatment.

Q: Does Moladerm affect the way other medicines are absorbed?

Official drug information describes the drug's role as a substrate for and/or inhibitor of certain metabolic enzymes (CYP3A4) and transport proteins (P-glycoprotein or P-gp). These biological mechanisms can affect how the body processes and handles other co-administered medications, potentially altering their levels.

Q: Does Moladerm interact with hormonal birth control?

Regulatory warnings for certain vaginal formulations indicate that the non-medicinal ingredients in the product may damage latex products, such as contraceptive condoms or diaphragms. Official guidance describes that concurrent use with these barrier methods may be inadvisable due to the potential for damage and contraceptive failure.

Q: Do I need to stop taking my vitamins while using Moladerm?

Official drug interaction summaries primarily focus on interactions with prescription medications and specific herbal supplements that are known to interfere with drug metabolism. General vitamins or mineral supplements are typically not listed in the dedicated interaction sections of the regulatory labels.

Q: How long does it usually take to notice any effects from Moladerm?

Official regulatory information focuses primarily on the total required duration of treatment rather than the exact day-to-day onset of symptom change. The product label specifies that if symptoms do not improve within a certain timeframe (e.g., 2 weeks for jock itch, 4 weeks for athlete’s foot), consulting a healthcare provider is noted to be necessary. This timeframe is often used as a benchmark for expected efficacy.

Q: What are the general expectations for a patient starting Moladerm treatment?

General expectations are guided by the patient directions provided in the regulatory documentation. These documents specify that the treatment involves preparatory steps, such as cleaning and drying the affected area before application. They also set a clear timeframe after which a lack of symptom improvement indicates the need for contact with a healthcare provider.

Q: Why do some people need to adjust their Moladerm dose after some time?

Dose adjustments may be required for patients who are concurrently taking other medicines that interfere with how Moladerm is processed by the body. For medicinal products that moderately affect these drug-metabolism pathways, regulatory documents indicate that adjustments may be necessary to maintain safe and approved levels of exposure for both medications.

Q: What should I do if I experience a persistent, unusual headache while on Moladerm?

While most commonly reported adverse effects for Moladerm are localized skin reactions, headache is listed as a potential adverse event for some formulations. Drug labels generally describe that if any severe or unusual symptoms, such as a persistent headache, occur, discontinuation of the medication and consultation with a healthcare provider are generally recommended.

Q: Is it normal to experience mild stomach upset when using Moladerm?

Systemic reactions like stomach upset or other gastrointestinal issues are not listed among the most frequently documented adverse effects for the topical formulation. The most common issues described in official safety documents are non-systemic, localized skin burning and irritation at the application site. However, less common reactions for certain formulations may include nausea or vomiting.

Q: Is it common to feel a little dizzy when first starting Moladerm?

Dizziness is not listed among the common or most frequently documented adverse effects for Moladerm products. The official safety profile focuses on non-systemic, localized reactions. Serious systemic side effects, which may include dizziness, are generally listed as 'low' frequency or 'Not Known' for the majority of topical formulations.

Q: What happens to the medicine in my body after I stop taking Moladerm?

Official drug information contains detailed, technical summaries describing how the medicine is eliminated from the body, including its half-life and elimination pathways. For optimal clinical results, adherence to the prescribed full course is generally considered necessary for ensuring the infection is cleared and minimizing the risk of resistance.

How should Moladerm be stored and disposed of?

How to Store and Dispose of Moladerm?

Moladerm (Miconazole Nitrate) must be stored according to regulatory labeling to maintain stability and prevent hazards. The product should be kept at Controlled Room Temperature, typically 20 to 25 C, and must not be frozen.


Storage Condition Requirement
Temperature Store below 30 C, at Controlled Room Temperature.
Protection Keep in the original container, tightly closed, protected from light and moisture.
Child Safety Must be kept out of the sight and reach of children and pets.
Special Handling Spray/powder forms must not be used near heat or an open flame.

Disposal of any unused or expired product must be done in accordance with local requirements and approved disposal guidelines to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Moladerm found in:

A-Z Index: